For health care professionals only

The information contained on this website is intended for use only by health care professionals in the United States. Countries outside of the United States may have different regulatory requirements or medical practices than the United States. Therefore, this information may not be appropriate for use outside of the United States.

Are you a health care professional in the United States?

You will now be leaving the NovoSeven® RT website.

NovoSeven® RT. Fast from the start. Fast to the finish.

  • When it comes to rapid reconstitution Reconstitution
    Adding liquid to prepare a medicine.     and
    administration Administration
    In hemophilia, to apply to the body through infusion.     , NovoSeven® RT is like no
    other bypassing agent Bypassing agent
    A product that treats a bleed without the need for Factor VIII (8) or Factor IX (9).
  • After entering the bloodstream, NovoSeven® RT
    starts working at the site of the
    injury to help form a stable clot Clot
    The thickened mass of blood and cells your body forms to stop the bleeding at the place where you have been injured.
  • NovoSeven® RT stops joint bleeds Bleed
    In hemophilia, a collection of blood in an area, such as a muscle or joint.
    in as few as 5 hours with as
    few as 2 doses*†

For bleeds that require more than 1 dose...why wait?

  • With NovoSeven® RT: You can readminister as quickly as every 2 hours‡
  • With plasma Plasma
    The fluid part of the blood that contains clotting factors and other proteins.     -derived bypassing agents (FEIBA®): You have to wait 12 hours before you can readminister‡

*Median of 2 doses.
†In patients with hemophilia A or B with and without inhibitors.
‡Based on individual dosage for joint bleeds in patients with hemophilia A or B with inhibitors.